Baseline demographics and disease characteristics
| IXE (n=283) | ADA (n=283) | |
| Baseline demographics | ||
| Age, years | 47.5 (12.0) | 48.3 (12.3) |
| Sex, n (%) | ||
| Male | 162 (57) | 150 (53) |
| Female | 121 (43) | 133 (47) |
| Race, n (%) | ||
| White | 222 (78) | 211 (75) |
| Asian | 29 (10) | 33 (12) |
| Weight, kg | 85.3 (19.8) | 81.9 (18.3) |
| Body mass index, kg/m2 | 30.0 (6.9) | 29.7 (8.3) |
| Duration of symptoms since PsA diagnosis, years | 6.6 (7.4) | 5.9 (6.4) |
| Duration of symptoms since psoriasis diagnosis, years | 16.1 (13.1) | 14.7 (12.6) |
| Concomitant csDMARD use, n (%) | 193 (68) | 199 (70) |
| Concomitant methotrexate use, n (%) | 167 (59) | 169 (60) |
| Baseline disease scores | ||
| Tender joint count | 19.1 (12.7) | 21.3 (15.4) |
| Swollen joint count | 10.1 (7.5) | 10.7 (8.1) |
| Patient pain VAS | 59.7 (21.9) | 62.4 (21.1) |
| Patient’s global assessment of disease activity VAS, mm | 62.4 (20.3) | 65.2 (20.7) |
| Physician’s global assessment of disease activity VAS, mm | 58.9 (17.5) | 59.4 (18.2) |
| HAQ-DI | 1.2 (0.6) | 1.3 (0.7) |
| C-reactive protein, mg/L | 9.8 (13.7) | 10.5 (19.3) |
| SPARCC Enthesitis Index >0, n (%) | 189 (67) | 171 (60) |
| SPARCC Enthesitis Index* | 4.9 (3.5) | 5.7 (3.8) |
| LEI >0, n (%) | 159 (56) | 147 (52) |
| LEI† | 2.5 (1.4) | 2.7 (1.5) |
| LDI-B >0, n (%) | 42 (15) | 58 (21) |
| LDI-B‡ | 40.1 (42.4) | 55.8 (128.4) |
| PASDAS | 5.8 (0.9) | 5.8 (1.0) |
| DAPSA | 42.7 (20.6) | 45.8 (23.5) |
| Moderate-to-severe psoriasis, n (%) | 49 (17) | 51 (18) |
| PASI ≥12, n (%) | 55 (19) | 57 (20) |
| sPGA ≥3, n (%) | 173 (61) | 181 (64) |
| BSA ≥3%, n (%) | 283 (100) | 283 (100) |
| BSA ≥10%, n (%) | 113 (40) | 104 (37) |
| PASI | 7.9 (8.7) | 7.7 (7.3) |
| Percentage BSA | 14.8 (18.4) | 12.9 (15.6) |
| DLQI | 9.8 (7.6) | 9.8 (7.6) |
| NAPSI fingernails >0, n (%) | 191 (68) | 177 (63) |
| NAPSI fingernails§ | 19.7 (18.5) | 19.1 (16.3) |
Unless indicated otherwise, data are presented as mean (SD).
*Assessed in patients with SPARCC Enthesitis Index >0 at baseline.
†Assessed in patients with LEI >0 at baseline.
‡Assessed in patients with LDI-B >0 at baseline.
§Assessed in patients with NAPSI >0 at baseline.
ADA, adalimumab; BSA, body surface area; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAPSA, Disease Activity in Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; HAQ-DI, Health Assessment Questionnaire–Disability Index; IXE, ixekizumab; LDI-B, Leeds Dactylitis Index–Basic; LEI, Leeds Enthesitis Index; NAPSI, Nail Psoriasis Area and Severity Index; PASDAS, psoriatic arthritis disease activity score; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; sPGA, static physician’s global assessment; VAS, visual analogue scale.